Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR ≤0.5 g/g) achieved in one-third of patients and sustained through one yearTwo indirect treatment comparisons indicate that EMPAVELI was superior to iptacopan in reducing proteinuria and achieving the composite renal endpoint in patients with C3G WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today ann ...

Core Insights - Apellis Pharmaceuticals will host a conference call on October 30, 2025, to discuss its third quarter 2025 financial results [1] - The call will be accessible via phone and a live audio webcast, with a replay available for 90 days [2] Company Overview - Apellis Pharmaceuticals is a global biopharmaceutical company focused on complement science, developing therapies for challenging diseases [3] - The company has introduced the first new class of complement medicine in 15 years, with two C3-targeting medicines approved for four serious diseases [3] - Notable breakthroughs include the first therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients aged 12 and older with C3G or primary IC-MPGN, both severe kidney diseases [3] - Apellis believes there is significant potential in targeting C3 across various serious diseases [3]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the Oversold Growth Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) since the company released its fiscal second quarter 2025 results. The company posted $178.49 million in revenue, down 10.61% year-over-year and below expectations by $10.15 million. On the bright side, the EPS of negative $0.33 topped estimates by $0.15. Management noted that they are proud of the FDA approval of EMPA ...

Question-and-Answer SessionSo maybe kick things off for us, if you would, just with a company overview, kind of where Apellis has been at and what's on the near-term horizon?Cedric FrancoisCo-Founder, President, CEO & Director Thank you, Colleen, and great to be back here for, I don't know, how many years now. It's always wonderful. So Apellis is a company that's focused on the complement pathways, specifically on complement factor C3, which is central in that cascade and allows you to have that unique and ...

Company Overview - Apellis is focused on the complement pathways, specifically on complement factor C3, which allows for unique and broad control of the complement pathway regardless of the source of activation [2] - The company is recognized as a global leader in this field and currently has three approved products on the market [2] Product Approval and Impact - The initial approval for EMPAVELI occurred in 2021 for the treatment of paroxysmal nocturnal hemoglobinuria, a blood-based disease caused by a mutation that makes red blood cells prone to destruction by the complement pathway [3] - EMPAVELI has been described as a life-changing option for patients suffering from this condition [3]

Apellis Pharmaceuticals (NasdaqGS:APLS) 2025 Conference September 09, 2025 10:15 AM ET Company ParticipantsCedric Francois - Co-Founder, President & CEOTimothy Sullivan - CFOConference Call ParticipantsColleen Kusy - Senior Research AnalystColleen KusyGood morning, everyone. Thanks for being with us for Baird's Global Healthcare Conference. My name is Colleen Cousy. I'm one of the Senior Analysts covering biotech at Baird. This morning, I'm pleased to have with me the team from Apellis Pharmaceuticals, incl ...

Core Insights - Apellis is currently leading the field in complement therapies with two approved products, SYFOVRE and EMPAVELI, and has a promising pipeline ahead [2][3] - The company has been successfully launching EMPAVELI for PNH for a couple of years and recently received approval for C3G and IC-MPGN, presenting significant opportunities to impact patient lives [3] Company Overview - Apellis has established itself as a leader in complement therapies, focusing on complement factor C3, which plays a crucial role in controlling downstream effects of the complement cascade [2] - The company is positioned for growth with its innovative products and expanding indications, particularly in the latter part of the year [2][3]

Summary of Apellis Pharmaceuticals (APLS) 2025 Conference Call Company Overview - **Company**: Apellis Pharmaceuticals (APLS) - **Date**: September 04, 2025 - **Focus**: Launch of new drugs, particularly in the complement inhibition space with products Ciforvi and Empavelli Key Points Current State and Outlook - Apellis is positioned as a leader in the complement inhibition field with two products on the market: Ciforvi and Empavelli [3][5] - The company is experiencing stable growth with guidance of low to mid single-digit growth for Ciforvi over the next several quarters [3][4] Product Launch and Market Dynamics - The launch of Empavelli for C3G and ICMPGN is progressing as expected, with a focus on addressing unmet needs in these disease areas [6][9] - Approximately 5,000 patients have been identified with C3G and ICMPGN, highlighting the significant unmet need [7][8] - The company is optimistic about the gradual uptake of Empavelli, emphasizing the importance of patient education and the functional benefits of the drug [9][10] Clinical Trials and Pipeline - Ongoing Phase 2 trial combining subcutaneous injection with Ciforvi aims to extend the dosing interval from every two months to every three months [4] - Two Phase 3 clinical trials for FSGS and delayed graft function are set to begin enrollment in the latter part of the year [4][52] - The company is also exploring preclinical programs that will be discussed in the following year [4][63] Financial Position - Apellis has a stable financial situation, ending the quarter with $370 million in the bank, which is expected to support the path to profitability [5][57] - A recent royalty deal with Sobe has strengthened the balance sheet and provided a growth platform [5][58] Competitive Landscape - Ciforvi is currently the market leader in new injections and total market share, with a recent shift in new treatment share favoring Ciforvi at approximately 55% [30][31] - The company is focused on generating additional data to maintain its competitive edge and grow the overall market [33][34] Regulatory and Market Access - Apellis is confident in navigating the regulatory landscape for its products, particularly in the context of delayed graft function [56] - The company is working on reimbursement strategies and co-pay assistance to ensure patient access to treatments [17][48] Future Developments - The company is exploring innovative approaches, such as functional OCT measurements, to enhance understanding of treatment impacts and patient experiences [38][41] - Apellis is also engaged in gene editing programs that aim to reduce immunoglobulin levels without affecting albumin, indicating a focus on novel therapeutic avenues [63][64] Additional Insights - The company is optimistic about the potential for Empavelli in transplant patients, which could change treatment paradigms in this area [22][23] - There is a strong emphasis on educating healthcare providers about the serious implications of diseases treated by Apellis, which could enhance market penetration [20][34] This summary encapsulates the key discussions and insights from the Apellis Pharmaceuticals conference call, highlighting the company's strategic direction, product pipeline, and market positioning.

Company Overview - Apellis is a commercial biopharmaceutical company focused on the complement biology system, which is part of the innate immune system [2] - The company targets diseases within the complement system, specifically at the central point known as C3 [3] Product Information - Apellis has developed two commercial drugs aimed at addressing diseases related to the complement system [3]